Brown & Brown is scheduled to report Q4 2025 results on January 26, 2026. Analysts forecast earnings per share of $0.89, representing a 3.5% increase versus the same quarter last year. Revenue is expected to reach approximately $1.65 billion, a rise of 35.8% from Q4 2024. This topline growth reflects both net new and renewal business, as well as higher organic revenues driven by increased premium volume across property, casualty and specialty lines.

In December the firm launched Brown & Brown Healthcare, its National Healthcare Practice comprising over 140 dedicated specialists. This unit provides risk and insurance solutions tailored to hospitals, health systems and physician groups, leveraging the company’s national footprint of more than 700 offices. Management projects the practice will manage in excess of $2.5 billion in annualized premiums by the end of 2026, enhancing market access for existing clients and targeting hundreds of new healthcare organization engagements.

Brown & Brown’s board declared a quarterly cash dividend of $0.165 per share, payable February 11, 2026, to shareholders of record on February 4. The company maintains a balanced capital structure, with a debt-to-equity ratio of 0.64 and a current ratio of 1.18, underscoring its liquidity. Valuation multiples include a price-to-earnings ratio of 26.05 and an enterprise-value-to-sales ratio of 6.31, reflecting investor confidence in the firm’s growth trajectory and ability to convert revenue gains into earnings.